Trial reportInternational journal of cardiology2026
Interleukin-1 blockade in patients with ST-segment elevation myocardial infarction with and without history of coronary artery disease.
Trial report in International journal of cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPatients with a history of coronary artery disease (CAD) presenting with ST-elevation myocardial infarction (STEMI) have high risk. We aimed to determine whether patients with CAD history presenting with STEMI had greater systemic inflammation and/or whether they benefitted similarly from IL-1 blockade.
methodsWe pooled data from three randomized clinical trials, including 139 patients with STEMI treated with anakinra or placebo. Patients were stratified by history of CAD defined as prior documented CAD, MI or coronary revascularization. The area under the curve (AUC) for C-reactive protein (CRP) was used to assess systemic inflammation. Event-free survival defined as the time from enrollment to the occurrence of a predefined adverse outcome, including new-onset heart failure, hospitalization for heart failure, or death, was compared using Cox regression analysis.
resultsOf the 139 patients, 113 (81 %) had no history of CAD, while 26 (19 %) had a history of CAD. The CRP-AUC was significantly lower in the anakinra group compared placebo, independent of history of CAD: 85 [47-137] vs. 349 [154-580] mg·day/L for anakinra and placebo, respectively, in patients with history of CAD, and 86 [43-179] vs. 213 [115-341] mg·day/L in patients without CAD history; p for interaction = (0.27). No significant interactions were found between history of CAD and treatment allocation for the composite outcome for patients with and without history of CAD, respectively, p for interaction = (0.48).
conclusionIL-1 blockade with anakinra in STEMI leads to similar reductions in systemic inflammation and improvement in HF-related outcomes inpatients both with and without history of CAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.